Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination

PHASE2RecruitingINTERVENTIONAL

Enrollment

230

Participants

Timeline

Start Date

July 5, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2027

Conditions

Varicella

Interventions

BIOLOGICAL

MG1111 (BARICELA)

0.5ml, single dose, subcutaneous injection

BIOLOGICAL

VARIVAX

0.5ml, single dose, subcutaneous injection

BIOLOGICAL

Suduvax

0.5ml, single dose, subcutaneous injection

Trial Locations (1)

RECRUITING

Korea University Ansan Hospital, Ansan